Kanał APM
AP

Aptorum Group Limited

APM · NASDAQ

$8.26 -12.13% (-$1.14)
Analiza

Raport AI o biznesie, finansach, wycenie, sentymencie, wiadomościach i ryzykach - napisany w kilka minut.

Piotroski F-Score Weak
2/9
Valuation
-
N/A
P/FCF N/A
P/S N/A
P/B N/A
Growth
-
N/A
Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A
ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A
Debt/Assets N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
0 /100
Unstable
Beta 0.17x
EPS volatility N/A
Profitable years N/A

Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej

Zapytaj StockBota o APM
Online

O spółce

Aptorum Group Limited (APM) is a global biotechnology company focused on the development of new drug candidates for the treatment of various diseases. Their research targets the treatment of infectious diseases, neurological and gastrointestinal disorders, oncological diseases, and other serious health conditions. Aptorum Group focuses on innovative therapeutic approaches, including the use of AI and bioinformatics technologies to discover new drug targets and therapies. The company is also active in the development of herbal-based medicines and traditional healing practices. Their aim is to bring innovative and effective therapeutic approaches to improve the health of patients worldwide. Aptorum Group Limited (APM) shares could be suitable for investors seeking investments in biotechnology companies with potential for innovative therapeutic development and global growth.

Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.

Sector

Healthcare

Industry

Biotechnology

CEO

Ian Huen

Employees

2

Headquarters

Princeton

Używamy niezbędnych plików cookie do działania strony oraz opcjonalnych analitycznych plików cookie do pomiaru ruchu. Zobacz naszą Politykę prywatności.